The tech company applies AI to DNA sequencing to aid clinicians in the diagnosis and treatment of patients.
This photo has been cropped and resized. Courtesy of SOPHiaGENETICS.COM.
Health-tech company SOPHiA Genetics, today announced the closing of a $77 million funding round to accelerate the democratization of data-driven medicine.
SOPHiA, founded in Switzerland and now co-based in Lausanne and Boston, applies artificial intelligence (AI) algorithms to DNA sequencing.
The company has now raised a total of $140 million in funding and plans to use the most recent funding to grow the number of hospitals using its technology and to expand its team.
Funding was led by Generation Investment Management, with additional investments from Idinvest Partners and existing investors Balderton Capital and Alychlo.
“With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide,” said Jurgi Camblong, Ph.D., CEO and founder of SOPHiA Genetics.
Its platform, SOPHiA AI, is used by more than 850 hospitals across 77 countries and has supported the diagnoses of more than 300,000 patients. SOPHiA AI aids healthcare professionals to make sense of complex genomic and radiomic data through analysis to drive better diagnosis and treatment for patients with oncology or hereditary disorders.
“We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system,” said Lilly Wollman, co-head of Generation’s growth equity team.
This is just the latest round of funding for the startup that was founded in 2011.
Last fall, SOPHiA closed a $30 million Series D round led by Balderton Capital and 360 Capital Partners.
Get the best insights in healthcare analytics directly to your inbox.